Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Cagrilintide for Sale > Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - large image1
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image1
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image2
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image3
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image4
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image5
Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product buy - image6

Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product

TDS 62 Inquiries

Unit Price:

$40/UNIT FOB

Get Latest Price
CAS No.:

1415456-99-3

Grade:

Research Grade

Content:

99%

Port:

深圳

Brand:

Generic

Packaging:

5mg/Vial

Price valid (until):

2026-10-07

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Peptides

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Name:Elare

    Whatsapp:+852 5535 7215

    Please add me for our latest price list and COA


      Product Detail  




      1. Cagrilintide 5mg Peptide Research Material

        Cagrilintide 5mg is a peptide research material supplied in a nominal 5mg specification. The product is provided in powder form and is intended for laboratory research and analytical purposes only. This description provides objective product information, including product identification, specification, physical form, quality considerations, packaging, storage and handling information, and general regulatory guidance.

        Product Information
        Product Name: Cagrilintide
        Specification: 5mg
        Product Type: Peptide Research Material
        Physical Form: Powder
        Appearance: White to off-white powder, subject to the applicable batch specification
        CAS No.: 1415456-43-3
        Intended Use: Laboratory research and analytical purposes only
        Product Overview

        Cagrilintide 5mg is supplied as a peptide research material in a defined 5mg quantity. The product is provided in powder form for laboratory-scale research and analytical applications where a specified peptide material is required.

        The product name, specification, and physical form are provided for product identification purposes. Product identity, purity, appearance, and other technical characteristics should be determined according to the applicable product specification and batch-specific documentation.

        This product listing is limited to objective research-material information. It does not make claims regarding therapeutic efficacy, weight management, appetite-related effects, clinical performance, disease prevention, disease treatment, or other medical applications.

        Product Specification

        The stated specification is 5mg, referring to the nominal quantity of material supplied.

        The 5mg specification should not be interpreted as a concentration, dosage, recommended administration amount, or clinical dose. It indicates the stated quantity of research material contained in the applicable package.

        Additional technical specifications should only be included when supported by authentic product documentation. Depending on the applicable quality specification, information may include product identity, purity, appearance, batch information, and analytical results.

        Any numerical quality parameters displayed on the product page should correspond to the actual production batch and supporting analytical documentation.

        Appearance and Physical Form

        Cagrilintide 5mg is supplied as a solid powder. Where consistent with the applicable product specification, the appearance may be described as white to off-white powder.

        Minor differences in physical appearance may occur between production batches. Final acceptance criteria should therefore be determined according to the relevant product specification and quality-control procedures.

        No unsupported statements regarding solubility, melting point, stability, sterility, or other physicochemical properties should be added unless such characteristics are confirmed by appropriate technical documentation.

        Quality Information

        Product quality should be evaluated using appropriate analytical procedures and batch-specific documentation.

        Where available, a Certificate of Analysis (COA) may provide information such as:

        Product identification
        Appearance
        Purity
        Batch information
        Analytical results
        Other applicable quality parameters

        Any purity value or analytical result displayed in the product listing should be supported by the corresponding documentation.

        If a particular quality parameter has not been verified, it should not be presented as a guaranteed specification.

        Packaging

        Cagrilintide 5mg should be supplied in packaging appropriate for the actual material and consistent with the applicable product documentation.

        The actual container type, package configuration, labeling, and quantity should correspond to the product being supplied.

        Terms such as “sterile,” “pharmaceutical grade,” “clinical grade,” or “approved for human use” should not be included unless supported by valid and applicable documentation.

        Storage and Handling

        The product should be stored and handled according to the applicable technical documentation and established laboratory procedures.

        The material should remain appropriately contained when not in use. Laboratory personnel should follow institutional safety procedures and use suitable protective measures based on the applicable risk assessment and available safety information.

        Specific storage temperature, shelf life, stability period, or handling conditions should only be stated when supported by relevant product documentation.

        Intended Use

        Cagrilintide 5mg is supplied as a research material for laboratory and analytical use only.

        The product is not presented as a food ingredient, dietary supplement, consumer product, or finished pharmaceutical product.

        This listing does not provide instructions for administration to humans or animals and does not provide dosage recommendations.

        Researchers and professional users are responsible for evaluating the suitability of the material for their specific laboratory applications and for following applicable institutional procedures and regulations.

        Regulatory Information

        Regulatory requirements may vary depending on the country or region, transportation method, intended application, and other relevant factors.

        This product description does not independently classify Cagrilintide as a hazardous chemical and does not assign a specific hazard category, transportation classification, or regulatory designation without supporting documentation.

        Where regulatory classification is required, it should be determined using the actual product documentation, applicable Safety Data Sheet (SDS), and current regulations in the relevant jurisdiction.

        If ECHEMI or the destination market requires specific qualifications, certificates, SDS documentation, or other regulatory materials, the applicable documents should be provided according to the actual product status and applicable requirements.

        Safety Documentation

        Where applicable, supporting documents may include:

        Certificate of Analysis (COA)
        Safety Data Sheet (SDS)
        Product Specification Sheet
        Batch-specific analytical documentation
        Other applicable technical documents

        All documentation should correspond to the actual product and, where applicable, the relevant production batch.

        Regulatory or safety information should not be inferred solely from the product name. Any specific regulatory statement should be supported by appropriate documentation.

        Product Listing Compliance

        The information provided in this listing is intended for product identification and general research reference.

        It does not constitute medical advice, pharmaceutical labeling, clinical guidance, therapeutic advice, or a recommendation for human or veterinary use.

        The product name, specification, CAS number, appearance, purity, packaging information, and other technical parameters should accurately correspond to the actual product and available supporting documentation.

        The 5mg specification indicates the nominal product quantity and should not be interpreted as a dosage, treatment amount, or recommended administration quantity.

        Any product characteristic that cannot be verified through appropriate documentation should be omitted rather than presented as a confirmed specification.

        Research Use Statement

        Cagrilintide 5mg is intended for laboratory research and analytical purposes only. Not for human or veterinary use.

        The product should be handled by appropriately trained personnel in a suitable laboratory environment. Storage, transportation, importation, exportation, and distribution should comply with applicable laws, regulations, and institutional requirements.

        General Compliance Disclaimer

        Product information and regulatory requirements may vary between markets. Buyers, distributors, and professional users should verify the requirements applicable to their location and intended activity.

        This listing intentionally avoids unsupported statements regarding weight management, appetite suppression, metabolic effects, therapeutic benefits, clinical applications, recommended dosage, disease treatment, or consumer use.

        Likewise, this description does not independently assign a hazardous-chemical classification. Where an SDS, hazard classification, transportation information, qualification document, or other regulatory material is required, the relevant information should be taken directly from authentic and applicable documentation.

        Product Summary

        Cagrilintide 5mg is a peptide research material supplied as a 5mg powder specification. The product is presented for laboratory research and analytical purposes, with product characteristics and quality parameters subject to the applicable product documentation.

        Research Use Only. Not for Human or Veterinary Use.



    Items Specifications
    Product Name Cagrilintide
    Grade Research Grade
    Package 5mg/Vial
    Appearance White Lyophilized Powder
    Model Cagrilintide 5mg
    Brand Generic

    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 1

    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 2
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 3
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 4
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 5
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 6
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 7
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 8
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 9
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 10
    ECHEMI Editorial Reference

    Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Certificates
    • Cagrilintide 5mg Research Peptide, Powder Form, 5mg Vial, Laboratory Research Product Certificates 1 TDS

    Basic Info
    Product Name:

    Cagrilintide

    Other Name:

    Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin

    CAS No.:

    1415456-99-3

    Molecular Weight:

    0

    EC Number:

    206-141-6

    Color/Form:

    White to off-white

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides

    Location:

    Y17, Room 310, East Third Floor, No. 64 and 66 Jianzhong Road, Tianhe District, Guangzhou City

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    1

    Total Employees:

    11-50

    Year of Establishment:

    2026

    Founded in 2024, PGpeptides is a specialized supplier of high-purity
    research peptides serving the global scientific community. With deep
    industry expertise, we deliver consistent product quality, competitive
    pricing, and flexible service tailored to research institutions, laboratories,
    and distributors worldwide.
    Our operations span North America, Europe, Asia, Australia, and the
    Middle East, backed by a mature international trade infrastructure and a
    reliable global fulfillment network. We have earned strong recognition 
    and trust across the markets we serve.
  • Inquiry History
    62 Inquiries
    Country Product Purchase Quantity Date Posted
    Australia

    Cagrilintide

    20 MG Aug 17, 2026
    United Kingdom

    Cagrilintide

    10 MG Jul 31, 2026
    France

    Cagrilintide

    10 MG May 22, 2026
    Australia

    Cagrilintide

    4 MT Mar 9, 2026
    United States

    Cagrilintide

    15 MG Feb 25, 2026
    United States

    Cagrilintide

    10 PCS Dec 27, 2025
    United States

    Cagrilintide

    2 MT Dec 21, 2025
    United States

    Cagrilintide

    100 MG Oct 28, 2025
    United States

    cagrilintide

    2 MT Aug 8, 2025
    Philippines

    Retatrutide

    5 MG Aug 5, 2025
    China

    Cagrilintide

    100 G May 6, 2025
    United States

    cagrilintide

    5 MG Feb 18, 2025
    United States

    Cagrilintide

    3 MT Feb 7, 2025
    United States

    Cagrilintide

    100  Nov 12, 2024
    United States

    Cagrillintide Lyophilized powder

    100 MG Jul 4, 2024
    United States

    Cagrillintide Lyophilized powder

    1000 MG Apr 20, 2024
    United States

    Cagrilintide

    25 MG Aug 31, 2026
    United States

    Cagrlintide

    1 MT Jul 31, 2026
    United Kingdom

    cagrilintrude

    20 MG Jul 21, 2026
    United States

    Cagrilintide

    1 KG Jul 17, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.